Informações:
Falhas:
ID
24993
Descrição
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00480090
Link
https://clinicaltrials.gov/show/NCT00480090
Palavras-chave
Versões (1)
- 23/08/2017 23/08/2017 -
Transferido a
23 de agosto de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Prostate Cancer NCT00480090
Eligibility Prostate Cancer NCT00480090
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00480090
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Prostate carcinoma Biopsy | Secondary malignant neoplasm of prostate | Serum PSA Increased
Item
biopsy-proven prostate cancer or clinical picture consistent with metastatic prostate cancer with high level of serum psa (> 20ng/ml)
boolean
C0600139 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C0347001 (UMLS CUI [2])
C1883014 (UMLS CUI [3])
C0005558 (UMLS CUI [1,2])
C0347001 (UMLS CUI [2])
C1883014 (UMLS CUI [3])
Docetaxel | Serum Prostate Specific Antigen Increased Measurement Quantity
Item
at least 4 weeks after docetaxel treatment and have at least 2 consecutive rising psas measured at least 2 weeks apart
boolean
C0246415 (UMLS CUI [1])
C1883014 (UMLS CUI [2,1])
C0242485 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C1883014 (UMLS CUI [2,1])
C0242485 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Docetaxel | Disease Progression | Intolerance to docetaxel
Item
progression on or intolerance of docetaxel chemotherapy
boolean
C0246415 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C1744706 (UMLS CUI [3,1])
C0246415 (UMLS CUI [3,2])
C0242656 (UMLS CUI [2])
C1744706 (UMLS CUI [3,1])
C0246415 (UMLS CUI [3,2])
ECOG performance status
Item
ecog performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
Organ function | Bone Marrow function
Item
adequate organ and marrow function
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
Cytarabine
Item
prior treatment with cytarabine
boolean
C0010711 (UMLS CUI [1])
Investigational New Drugs | Antineoplastic Agents
Item
receiving any other investigational or anticancer agents
boolean
C0013230 (UMLS CUI [1])
C0003392 (UMLS CUI [2])
C0003392 (UMLS CUI [2])
Comorbidity Uncontrolled
Item
uncontrolled intercurrent illness
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,2])
Malignant Neoplasm Site Other | Exception Squamous cell carcinoma of skin | Exception Basal cell carcinoma
Item
active malignancy at any other site excluding squamous cell or basal cell carcinomas of the skin
boolean
C0006826 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0553723 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1515974 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0553723 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
Therapeutic radiology procedure
Item
radiotherapy within the past 4 weeks
boolean
C1522449 (UMLS CUI [1])